[铂敏感复发性卵巢癌再次铂类化疗疗效的相关因素分析]
[Related-factor analysis on efficacy of re-platinum chemotherapy in platinum-sensitive recurrent ovarian carcinoma].
作者信息
Cheng Xiao-dong, Lü Wei-guo, Xie Xing, Huang Xiu-feng, Ye Da-feng, He Hong-cheng, Ding Zhi-ming
机构信息
Department of Gynecological Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
出版信息
Zhonghua Fu Chan Ke Za Zhi. 2003 Nov;38(11):670-2.
OBJECTIVE
To analysis the related factors of efficacy of re-platinum chemotherapy in platinum-sensitive recurrent ovarian carcinoma.
METHODS
Forty-one patients with platinum-sensitive recurrent ovarian cancer from Jan. 1998 to Oct. 2002 were reviewed, 37 factors were analyzed, including age, the optimal of primary surgery, number of chemotherapy cycles, standard chemotherapy or not, serum CA(125) level, follow up or not, relapse interval, the site and the number of relapse lesion, et al.
RESULTS
Response rate of chemotherapy was 56%, the toxicity was not serious. Response rate of standard chemotherapy was 76% (19/25), not standard chemotherapy was 25% (4/16), standard chemotherapy or not was the only factor related to efficacy (P < 0.05).
CONCLUSION
Re-platinum chemotherapy to platinum-sensitive recurrent ovarian carcinoma is reasonable, standard chemotherapy or not affects the response rate.
目的
分析铂敏感复发性卵巢癌再次铂类化疗疗效的相关因素。
方法
回顾性分析1998年1月至2002年10月期间41例铂敏感复发性卵巢癌患者，分析37项因素，包括年龄、初次手术的彻底性、化疗周期数、是否进行标准化疗、血清CA125水平、是否随访、复发间隔、复发部位及复发灶数量等。
结果
化疗有效率为56%，毒性不严重。标准化疗的有效率为76%（19/25），非标准化疗为25%（4/16），是否进行标准化疗是唯一与疗效相关的因素（P<0.05）。
结论
铂敏感复发性卵巢癌再次铂类化疗是合理的，是否进行标准化疗影响有效率。
Zotero 插件